Bamco Inc. NY Has $70.05 Million Stock Position in Establishment Labs Holdings Inc. $ESTA

Bamco Inc. NY reduced its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 18.7% in the 4th quarter, HoldingsChannel reports. The firm owned 961,226 shares of the company’s stock after selling 220,598 shares during the period. Bamco Inc. NY’s holdings in Establishment Labs were worth $70,054,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Quarry LP acquired a new stake in Establishment Labs during the 3rd quarter valued at $34,000. Kestra Advisory Services LLC acquired a new stake in Establishment Labs during the 4th quarter valued at $47,000. Osaic Holdings Inc. lifted its holdings in Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after purchasing an additional 1,800 shares during the last quarter. Truist Financial Corp acquired a new stake in Establishment Labs during the 4th quarter valued at $200,000. Finally, PharVision Advisers LLC acquired a new stake in Establishment Labs during the 3rd quarter valued at $203,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of Establishment Labs stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the sale, the director owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. This trade represents a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 330,000 shares of company stock worth $22,854,538 over the last three months. 9.99% of the stock is currently owned by company insiders.

Establishment Labs Stock Down 0.2%

ESTA opened at $82.39 on Thursday. Establishment Labs Holdings Inc. has a fifty-two week low of $33.35 and a fifty-two week high of $86.00. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96. The company has a market capitalization of $2.42 billion, a P/E ratio of -55.29 and a beta of 1.11. The stock has a fifty day moving average of $70.25 and a 200-day moving average of $69.48.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The firm had revenue of $59.88 million for the quarter, compared to analyst estimates of $57.40 million. During the same period in the prior year, the business posted ($0.70) EPS. The firm’s quarterly revenue was up 44.7% compared to the same quarter last year. On average, equities analysts expect that Establishment Labs Holdings Inc. will post -1.07 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. TD Cowen reaffirmed a “buy” rating on shares of Establishment Labs in a report on Monday, June 8th. Mizuho raised their price target on Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Wall Street Zen downgraded Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. Finally, BTIG Research raised their price target on Establishment Labs from $88.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Establishment Labs has an average rating of “Moderate Buy” and an average target price of $87.14.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.